ENHA
ANRO
FTH

Apeiron Investment Group Ltd.

Known title: 10% OwnerCIK: 0001845711

Apeiron Investment Group Ltd.'s purchase track record

Apeiron Investment Group Ltd. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.

PurchaseStockAmount3 months6 months
9/17/2026ENHA$6.99Mpendingpending
9/2/2026ENHA$496Kpendingpending
8/14/2026ENHA$3.56Mpendingpending
2/23/2023FTH$4K-14.8%-36.4%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 15, 2026

ENHA Listed in Consumer Discretionary Movers. Enhanced Group Inc. was highlighted in a recent list of consumer discretionary stocks moving during Tuesday's intraday session. The stock is currently trading near its 52-week low, with an RSI of 34.1 indicating oversold conditions. A volume spike signal is also active, suggesting increased trading activity around these levels.

this person other insiders at ENHA

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 14, 2026

ANRO mentioned in review of lagging medical stocks. A Yahoo article reviewing medical sector performance noted that many medical stocks have lagged behind Cardinal Health this year. Alto Neuroscience, as a medical‑focused company, is part of that broader discussion. The stock is currently near the lower end of its 52‑week range, which aligns with the sector’s weaker momentum.

this person other insiders at ANRO

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

William Blair Begins Coverage of Faeth Therapeutics (FTH). William Blair has started coverage of Faeth Therapeutics and issued an Outperform rating. The move may increase analyst attention and could influence market perception. The stock is currently trading below its 52‑week low and has a low RSI, indicating it is in a downtrend.

this person other insiders at FTH

Transaction History

ENHA▲ Buy$7.0M
ENHA▲ Buy$159K
ENHA▲ Buy$93K
ENHA▲ Buy$34K
ENHA▲ Buy$40K
ENHA▲ Buy$170K
ENHA▲ Buy$2.7M
ENHA▲ Buy$90K
ENHA▲ Buy$158K
ENHA▲ Buy$330K
ENHA▲ Buy$296K
ENHA▲ Buy—
ENHA▲ Buy—
ENHA▲ Buy—
ENHA▲ Buy—
ANRO▼ Sell—
ANRO▼ Sell—
FTH▼ Sell$1.5M
FTH▼ Sell$3.9M
FTH▲ Buy$2K
FTH▲ Buy$2K

We use analytics to understand how market-wall is used. No personal data is sold.